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OBJECTIVE — We compared the short-term efﬁcacy of home telemonitoring coupled with
active medication management by a nurse practitioner with a monthly care coordination tele-
phone call on glycemic control in veterans with type 2 diabetes and entry A1C 7.5%.
RESEARCH DESIGN AND METHODS — Veterans who received primary care at the
VA Pittsburgh Healthcare System from June 2004 to December 2005, who were taking oral
hypoglycemic agents and/or insulin for 1 year, and who had A1C 7.5% at enrollment were
randomly assigned to either active care management with home telemonitoring (ACMHT
group, n  73) or a monthly care coordination telephone call (CC group, n  77). Both groups
received monthly calls for diabetes education and self-management review. ACMHT group
participants transmitted blood glucose, blood pressure, and weight to a nurse practitioner using
the Viterion 100 TeleHealth Monitor; the nurse practitioner adjusted medications for glucose,
blood pressure, and lipid control based on established American Diabetes Association targets.
Measures were obtained at baseline, 3-month, and 6-month visits.
RESULTS — Baselinecharacteristicsweresimilarinbothgroups,withmeanA1Cof9.4%(CC
group) and 9.6% (ACMHT group). Compared with the CC group, the ACMHT group
demonstratedsigniﬁcantlylargerdecreasesinA1Cat3months(1.7vs.0.7%)and6months(1.7
vs. 0.8%; P  0.001 for each), with most improvement occurring by 3 months.
CONCLUSIONS — Compared with the CC group, the ACMHT group demonstrated sig-
niﬁcantly greater reductions in A1C by 3 and 6 months. However, both interventions improved
glycemic control in primary care patients with previously inadequate control.
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W
ithin the Veterans Health Ad-
ministration, 500,000 veter-
ans receive care for diabetes
annually; diabetes is a leading cause of
morbidity and mortality and a major con-
tributor to health care cost (1,2). Sam-
pling data from 2009 indicate that 28%
of veterans nationally have suboptimal
glycemic control with A1C 8% (3). In-
creases in A1C levels above the normal
range in patients with diabetes are associ-
ated with progressive increases in mor-
bidity and mortality due to micro- and
macrovascular disease (4). Intensive gly-
cemic control can reduce microvascular
complications in both type 1 and type 2
diabetes (5,6). However, recent studies
have not demonstrated that intensive gly-
cemiccontrolfor3–6yearswithachieved
A1Ctargetsfrom6.4to6.9%reducesma-
crovascular complications in patients
with long-standing type 2 diabetes (7–9).
In contrast, intensive glycemic control
initiated early in the course of either type
1 or type 2 diabetes appears to reduce the
riskofsubsequentmacrovascularcompli-
cations signiﬁcantly even when glycemic
control later deteriorates (10,11).
Home-based telemedicine has been
examined as a tool for management of
chronic diseases (12), including diabetes
(13–19). This approach can obviate geo-
graphic barriers; provide automated edu-
cation, feedback, and data transmission;
andfacilitateprovider-to-patientcommu-
nication (12). However, outcomes with
home telemonitoring in diabetes and
other chronic diseases have been variable
(12). Of several randomized controlled
trials (RCTs) using home telemonitoring
in diabetes care (13–19), only two have
reported signiﬁcant improvement in A1C
(17,18). Neither of these trials included
active medication management by a pro-
vider in response to real-time transmis-
sion of self-monitored blood glucose
(SMBG) data or have speciﬁcally targeted
patients not meeting glycemic control
goals in response to pharmacological
therapy under conditions of usual care.
The present study compared the efﬁ-
cacy of home telemonitoring coupled
with active medication management by a
nurse practitioner (ACMHT interven-
tion) with a lower-intensity care coordi-
nation intervention (CC intervention)
consisting of monthly telephone contact
withadiabetesnurseeducator.Ourstudy
speciﬁcally targeted veterans with A1C
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macological therapy under conditions of
usual care.
RESEARCH DESIGN AND
METHODS— TheDiaTelStudywasa
RCT of veterans with type 2 diabetes re-
ceiving their primary care at the VA Pitts-
burgh Healthcare System (VAPHS) at one
of the three main Pittsburgh campuses or
ﬁve outlying community-based clinics.
The study was approved by the VAPHS
Institutional Review Board and con-
ducted according to the principles of the
Declaration of Helsinki. All participants
provided signed informed consent.
Under a separate VAPHS-approved
protocol, a sampling frame of potentially
eligible veterans was developed from
VAPHS electronic medical and pharmacy
recordsusingthefollowingcriteria:hadat
leastoneoutpatientvisitinaprimarycare
clinic between 1 June 2004 and 31 De-
cember 2005, were aged 80 years, re-
ceived pharmacological treatment for
diabetesfor12months,hadnoreferrals
to the VAPHS Diabetes Clinic in the pre-
ceding 18 months, and had a most recent
A1C 8.0%. Approximately 20% of vet-
eranswithdiabetesinoursamplingframe
met that A1C criterion.
After review and approval by their
primary care providers (PCPs), poten-
tially eligible veterans were invited by let-
ter to participate. Nonresponders were
contacted by primary care clinic staff to
solicit their participation. The study was
described to interested veterans by re-
search staff who obtained signed consent.
Eligibility was further veriﬁed by a point-
of-care capillary A1C 7.5% at enroll-
ment using a DCA 2000 analyzer (Bayer
Healthcare). Veterans were excluded if
they had a life expectancy of 6 months,
were participating in another study, re-
sidedinaninstitutionalsetting,ordidnot
have a land-based, analog home tele-
phone line as required for the home tele-
monitoring device used.
Participants were randomly assigned
to the ACMHT or CC group. Random-
ization was stratiﬁed by quartile of capil-
lary A1C within each site and blocked on
time. The project statistician generated
the random sequences, the study nurses
enrolled the participants, and the study
coordinator informed the nurses of the
intervention assignment after each partic-
ipant was enrolled. After an initial educa-
tion session, participants were informed
of their intervention assignments. Be-
cause of the nature of the intervention,
neither participants nor study nurses
could be blinded. However, primary out-
comes were ascertained by personnel un-
connected to this study who were
unaware of intervention assignments. Re-
cruitment started 1 October 2005; the ﬁ-
nal 6-month follow-up was 11 January
2007.
Interventions
Participants in both groups attended an
initial2-heducationalsessionfordiabetes
self-management and nutrition. Partici-
pants randomly assigned to the
ACMHT group received a 6-month di-
abetes management support intervention
using the Viterion 100 Monitor home
telemonitoring device. The device per-
mits continuous home messaging with
reminders and education; ongoing moni-
toring of SMBG, blood pressure, and
weight; and daily transmission of these
data to study providers via a secure net-
work(20).Participantswereinstructedto
transmit uploaded measurements from
Viterion-compatibleperipheraldevicesto
the study nurse practitioner daily. On
Monday through Friday, the nurse prac-
titioner reviewed SMBG, blood pressure,
weight,andriskstratiﬁcationreportsgen-
erated by the Viterion and contacted par-
ticipants as necessary. The nurse
practitioner provided timely telephone
follow-up, including further self-
management education for participants
who generated “high-risk” reports based
on unacceptably high or low SMBG or
blood pressure readings. Medications for
glycemic, blood pressure, and lipid
control were adjusted by the nurse
practitioner supervised by the study
endocrinologistwithoutpriorapprovalof
the PCP who was informed retrospec-
tively of all changes. The nurse practitio-
ner maintained records of all medication
changes made in the ACMHT group.
The nurse practitioner also called
ACMHT participants monthly to pro-
vide individualized self-management
counseling tailored to speciﬁc issues,
based on the status of glucose and blood
pressure control from the transmitted
data.
Participants randomly assigned to
the CC group received monthly tele-
phone calls from the study diabetes
nurse educator regarding general health
conditions, status of glycemic control,
blood pressure, and weight from daily
logs maintained by the participants and
compliancewiththeprescribeddiabetic
regimen. Issues requiring active inter-
vention were referred to their PCP. Par-
ticipants also could initiate contact with
the study diabetes nurse educator to
discuss concerns related to diabetes
management.
Outcomes
Atbaseline,3months,and6months,par-
ticipants presented to VAPHS for mea-
surement of A1C, blood pressure, and
weight and a fasting lipid panel. Baseline
medication regimen (dose) and changes
in the regimen (dose and date) for oral
hypoglycemic agents, insulin, antihyper-
tensive medications, and lipid-lowering
medications were abstracted from the
electronic pharmacy records and veriﬁed
by participant interview.
Statistical methods
This study was designed to detect a 1%
differenceinA1Cwith80%powerusinga
0.05-level two-sided test. Improvement
was deﬁned in terms of mean differences
at 3 and 6 months as well as differential
change over time. The primary outcome,
A1C, was speciﬁed a priori. P  0.05 was
considered to be statistically signiﬁcant,
with no adjustment for multiple
comparisons.
Our intent-to-treat approach in-
cludedallrandomlyassignedparticipants
to the extent possible. Data features that
mandated special methods were the labo-
ratoryreportingofasmallnumberofA1C
values exceeding some cut point (trun-
cated values, i.e., reported as 11.5,
11.8, or 12.3%) and a few missing
A1C values. A modiﬁed multiple-
imputation approach was used to obtain
unbiased estimates, appropriate vari-
ances,andvalidtests,basedonachained-
equations algorithm (21) implemented in
STATA SE 9.2 (22).
Mean A1C, weight, blood pressure,
and lipid values were compared for the
ACMHT and CC groups at baseline, 3
months, and 6 months. The proportions
ofparticipantsineachgroupwhoreached
deﬁned clinical target values at each time
point were compared using Fisher’s exact
tests.
For each continuous outcome, differ-
ence scores were computed between each
pair of time points (baseline to 3 months,
baseline to 6 months, and 3 months to 6
months). Between-group comparisons of
difference scores were obtained by re-
gressingthedifferencescoresforeachpair
of time points on a dummy variable for
treatment group (if necessary to accom-
modate multiple imputation) or using a t
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compared with zero using linear regres-
sion including only an intercept or a t test
(as appropriate). The interaction of treat-
ment group and insulin status at baseline
was assessed. In the ACMHT group,
Pearson correlations summarized associ-
ations between A1C at 6 months and the
frequencies of SMBG and adjustments of
insulin.
RESULTS— Of the 1,055 veterans in
the initial sampling frame deemed appro-
priate for the study, 658 (62.4%) re-
sponded to letters of invitation to
participate and 381 (57%) agreed to be
contacted. Of these, 211 presented to
VAPHS for signed informed consent, ad-
ditional screening, and baseline measure-
ments. The 150 consenting veterans who
hadacapillaryA1C7.5%atthebaseline
wererandomlyassignedtotheACMHT
(n73)orCC(n77)groups.Ofthese,
3 ACMHT and 2 CC participants were
excludedbecausetheyweresubsequently
found to meet baseline exclusion criteria;
2 CC participants withdrew before the
initial education session and 6 ACMHT
participants withdrew afterward. This
analysis includes the remaining 64
ACMHT and 73 CC participants (sup-
plementary Table 4A, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1012/DC1).
All participants completed the base-
line assessment; 6 ACMHT and 4 CC
participants missed the 3-month assess-
ment and 8 ACMHT and 7 CC partici-
pants missed the 6-month assessment. A
total of 8 A1C values in the ACMHT
group and 9 A1C values in the CC group
were missing, and 10 A1C values were
truncated.
Baseline patient characteristics
There were no signiﬁcant differences by
treatment group for age, sex, race, or any
of the other baseline characteristics as
shown in supplementary Table A1. Ap-
proximately one-third of the participants
in both groups were aged 65 years; the
vast majority were male and non-
Hispanicwhite.Thepredominantcomor-
bidities were coronary artery disease and
congestive heart failure.
Medication management
Most participants in each group were tak-
ing oral hypoglycemic agents (predomi-
nantly glyburide and metformin) and
antihypertensiveandlipid-loweringmed-
ications at baseline, 3 months, and 6
months; 50% were using insulin (sup-
plementary Table A2). There were no sig-
niﬁcant differences by medication class at
any time point (P  0.14 for each). By 6
months, ACMHT participants had sig-
niﬁcantly more medication or dose
changes on average involving antihyper-
tensive agents (3.1 for ACMHT vs. 1.9
for CC participants, P  0.02), but not
lipid-lowering agents (1.4 for ACMHT
vs. 1.1 for CC participants, P  0.29) or
oral hypoglycemic agents (1.8 for
ACMHT vs. 1.8 for CC participants,
P  0.91).
At baseline, 39 ACMHT and 40 CC
participants were using insulin. By 6
months, 1 ACMHT and 1 CC partici-
pant had discontinued insulin, whereas 5
ACMHT and 3 CC participants had be-
gun insulin. Although the average daily
insulin dose was similar in both groups at
baseline, the average daily dose for
ACMHT participants was 18 IU
higher than that for CC participants at 3
and 6 months (P  0.02 and P  0.048,
respectively). The average number of ad-
justments in insulin dose was also higher
in ACMHT (6.6) than in CC (2.8) par-
ticipants (P  0.001). However, no sig-
niﬁcant correlation was found between
the frequency of insulin adjustment and
A1Cat6monthsineitherACMHT(r
0.12;P0.43)orCC(r0.14;P038)
participants.
Primary outcomes
Dotplots of individual values for A1C,
weight, blood pressure, and lipids are
shown by treatment group for each time
point in Fig. 1. Baseline values were sim-
ilar for both groups (P  0.45 for each)
(Table 1). A1C was signiﬁcantly lower for
ACMHT than for CC participants at
both 3 and 6 months (0.7% lower at each
time point, P  0.001 for each). Signiﬁ-
cantly greater decreases in A1C were ob-
served in the ACMHT group relative to
the CC group at 3 months (1.7 vs. 0.7%)
and6months(1.7vs.0.8%),correspond-
ing to differential decreases of 0.9%
(P  0.001 for each) (supplementary Ta-
ble A3). There was no signiﬁcant interac-
tion between baseline insulin usage and
treatmentresponseatanytimepoint(P
0.39 for each) (supplementary Fig. 1).
None of the other primary outcomes
differed signiﬁcantly by treatment group
at either 3 or 6 months (Table 1). How-
ever, except for weight and HDL choles-
terol levels, the direction of the
differences favored the ACMHT group.
Within both treatment groups, A1C,
blood pressure, cholesterol, and LDL im-
proved signiﬁcantly at 3 and 6 months
relative to baseline, whereas HDL de-
creased (supplementary Table A3). Trig-
lycerides declined signiﬁcantly from
baseline only in the ACMHT group. A
4-lb mean weight increase in the
ACMHT group was the only signiﬁcant
within-group change between 3 and 6
months.
SimilarproportionsofACMHTand
CC participants had A1C levels 8o r
9% at baseline (Table 2). However, at 6
months,20.3%ofACMHTand5.5%of
CC participants achieved A1C 7% (P 
0.01). Signiﬁcantly more ACMHT than
CC participants also reached A1C levels
of 8 and 9% at both 3 and 6 months
(P  0.03 for each). Less than half of the
participants had systolic blood pressure
130mmHgatanytimepoint,whereasa
majority met the targets for diastolic
blood pressure, LDL, and triglycerides. A
higher percentage of ACMHT than CC
participants met the LDL treatment target
of 100 mg/dl at 6 months (79.7 vs.
59.4%, respectively; P  0.02).
SMBG among ACMHT participants
Seven ACMHT participants (10.9%)
never transmitted any SMBG data after
initial training. Another 9 participants
(14.1%) performed SMBG on average 1
time per day, whereas 75.0% performed
SMBGbetween1and4timesperday(av-
erage2.3timesdaily)duringtheperiodin
which they transmitted measurements.
Among the 57 participants who transmit-
ted measurements, 35 (61.4%) transmit-
ted SMBG 50 mg/dl on at least 1 day
(median 1 day) and 16 (28.1%) transmit-
ted SMBG between 50 and 70 mg/dl (me-
dian 10 days). Within the ACMHT
group, the frequency of SMBG did not
correlate signiﬁcantly with reduction in
A1C (r  0.11; P  0.39).
Nurse-to-participant telephone con-
tact time was substantially greater in
ACMHTthanCCparticipants(1.3vs.
0.3h/participant/month,respectively).In
the ACMHT group, telephone contact
was triggered by transmitted suboptimal
SMBG or blood pressure levels. Thus,
contact time was disproportionately high
in this subgroup of ACMHT
participants.
One participant in the ACMHT
group died at home suddenly 7 months
after entry in the study. No postmortem
examination was obtained. The partici-
panthaddiabeticneuropathy,stageIVre-
nal insufﬁciency, and congestive heart
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recently. He was treated with insulin
alone and thus was taking no oral hypo-
glycemic agent that may have compli-
cated his heart failure. His A1C levels fell
from 11.8% at baseline to 6.5% at 3
months. Of his 468 transmitted SMBG
values, 4 (0.85%) were 50 mg/dl, a fre-
quency similar to that of ACMHT par-
ticipants overall (0.66%) and that
(0.59%) of 7 other ACMHT partici-
pants using insulin who had rapid de-
clines in A1C (3%) over 3 months. No
SMBG 50 mg/dl occurred during the
month before his death. The relation-
ships, if any, between the rapid decline in
A1C, hypoglycemia, and sudden death in
this patient are uncertain.
CONCLUSIONS — Participants in
this study had suboptimal glycemic con-
trolafteratleast1yearofpharmacological
therapy directed by a PCP. Each of the
interventionsusedinthestudyresultedin
Figure 1—Dot plots of the primary outcome measures (A1C, weight, systolic blood pressure, diastolic blood pressure, cholesterol, HDL, LDL, and
triglycerides)atbaseline,3months,and6monthsbytreatmentgroup.F,ACMHTgroup;E,CCgroup.Time-speciﬁcmeanvaluesareconnected
by solid black lines for the ACM  HT group and dotted lines for the CC group.
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ever, the latter were signiﬁcantly greater
in ACMHT compared with CC partici-
pants. The relative contributions of the
automated messaging and monitoring ca-
pacityprovidedbythehometelemonitor-
ing device, the nearly fourfold greater
nurse-to-participant telephone contact
time, and the greater intensiﬁcation of
insulin therapy in the ACMHT versus
CC group to the A1C outcomes cannot
be determined from our study design,
which is a limitation of the design. Self-
management education was an intrinsic
component of the more frequent nurse-
to-participant phone communications
in the ACMHT group and was additive
totheeducationalmessagingprovidedvia
the home telemonitoring device. A meta-
analysis of 31 RCTs indicated an associa-
tion between increased patient contact
time with a diabetes nurse educator and
lower A1C levels, with an estimated de-
crease in A1C of 1% for every additional
23.6 h of contact (23). This effect may
havecontributedsigniﬁcantlytothemore
marked reduction in A1C in the
ACMHT versus CC group. Greater in-
tensiﬁcation of insulin therapy in the
ACMHT group probably also contrib-
uted to the more marked declining A1C
compared with that of the CC group.
However,nosigniﬁcantcorrelationswere
found between the frequency of insulin
adjustments and A1C outcomes at 6
months in either group.
A majority (75%) of ACMHT par-
ticipants performed SMBG at least daily,
with a mean of 2.3 times per day. This is
muchmorefrequentthantheobservation
in the National Health and Nutrition Ex-
amination Survey (NHANES) (24), in
which 29% of patients with diabetes who
weretakinginsulin,65%whoweretaking
oral agents, and 80% who managed their
disease with diet alone performed SMBG
less than one time per month (24). Con-
sistent with NHANES data, which
showed no correlation between the fre-
quency of SMBG and A1C (24), we did
not ﬁnd a signiﬁcant association between
frequency of SMBG and magnitude of de-
cline in A1C within the ACMHT group.
Lack of SMBG data for the control group
is a limitation of our study, which pre-
cluded ascertainment of the relative fre-
quency of monitoring in the CC versus
ACMHT group, the relationship of
SMBG to the respective A1C outcomes,
and the relative frequency of hypoglyce-
miainthetwogroups.However,multiple
prior reports have indicated that the rela-
tionship between the frequency of SMBG
and glycemic control is complex and in-
consistent and may depend on coupling
SMBG with a structured plan for treating
glucose elevations (24,25). Full realiza-
tion of the beneﬁts of real-time transmis-
sion of SMBG indexes, whatever their
frequency, probably depend on the pre-
scriptive response of the provider receiv-
ing the data (25).
It is uncertain whether the improved
glycemic control observed in the
ACMHT group can be sustained be-
yond6monthswithorwithoutcontinued
active care management with home tele-
monitoring, and if sustained, will trans-
late into improved clinical outcomes.
Recent studies have failed to demonstrate
improved macrovascular outcomes with
intensive glycemic control among pa-
tients with type 2 diabetes (7–9). The Ac-
tion to Control Cardiovascular Risk in
Diabetes (ACCORD) trial (7) reported in-
creased mortality in a subgroup of type 2
diabetic patients subject to intensive gly-
cemic control. The VA Diabetes Trial (9)
suggested improved cardiovascular out-
comes occurred only in younger patients
with a shorter duration of diabetes and
also raised concern about an association
between hypoglycemia and cardiovascu-
lar events (9). Consistent with the VA Di-
Table 1—Time-speciﬁc primary outcomes by treatment group
CC group
ACM  HT
group DiffCC-ACM P
n 73 64
A1C (%)
Baseline 9.4  1.4 9.6  1.6 0.2 (0.7 to 0.3) 0.53
3 months 8.7  1.2 7.9  1.2 0.7 (0.3 to 1.2) 0.001
6 months 8.6  1.3 7.9  1.2 0.7 (0.3 to 1.2) 0.001
Weight (lb)
Baseline 223.5  47.9 226.6  45.4 3.1 (18.9 to 12.7) 0.70
3 months 222.0  49.6 225.5  44.5 3.5 (19.5 to 12.5) 0.67
6 months 223.9  48.6 229.5  47.6 5.7 (21.9 to 10.6) 0.49
Systolic blood pressure
(mmHg)
Baseline 142.3  19.0 144.8  21.7 2.6 (9.5 to 4.3) 0.46
3 months 137.1  21.4 135.9  23.3 1.2 (6.2 to 8.7) 0.74
6 months 133.0  19.0 132.0  24.3 1.0 (6.2 to 8.2) 0.79
Diastolic blood pressure
(mmHg)
Baseline 80.5  10.1 79.9  13.3 0.6 (3.4 to 4.5) 0.78
3 months 76.6  12.9 75.4  12.0 1.3 (2.9 to 5.4) 0.55
6 months 75.9  13.2 72.4  14.6 3.5 (1.1 to 8.2) 0.13
Cholesterol (mg/dl)
Baseline 175.6  43.5 177.3  54.2 1.7 (18.2 to 14.8) 0.84
3 months 160.8  37.5 149.8  37.2 11.0 (1.7 to 23.6) 0.09
6 months 159.1  37.2 148.2  40.2 11.0 (2.0 to 24.0) 0.10
HDL (mg/dl)
Baseline 38.4  13.0 38.4  13.5 0.0 (4.5 to 4.5) 0.99
3 months 36.2  11.0 35.0  10.7 1.3 (2.4 to 4.9) 0.50
6 months 36.4  13.6 35.1  11.3 1.3 (3.0 to 5.5) 0.55
LDL (mg/dl)†
Baseline 101.8  32.0 98.8  36.3 3.0 (8.9 to 15.0) 0.62
3 months 92.3  32.2 86.3  27.7 6.0 (4.6 to 16.6) 0.27
6 months 91.2  30.6 82.3  27.9 8.9 (1.6 to 19.3) 0.10
Triglycerides (mg/dl)
Baseline 194.1  160.4 191.3  133.3 2.7 (47.5 to 53.0) 0.92
3 months 170.0  133.6 149.9  114.1 20.1 (22.3 to 62.5) 0.35
6 months 170.7  115.9 152.4  99.7 18.3 (18.0 to 54.6) 0.32
Data are means  SD and mean differences (CC  ACM  HT) with 95% CIs for these differences at each
timepoint.CorrespondingPvaluesarealsoshown.Apositivedifference(DiffCC-ACM)indicatesthatthemean
for that outcome at that time point is lower in the ACM  HT group than in the CC group. *Because
measurements are rounded to one decimal place for reporting purposes, the rounded difference scores may
differ slightly from the differences of the rounded means. †CC group: n  69; ACM  HT group: n  59.
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from the UK Prospective Diabetes Study
(10) indicated that intensive glycemic
controlestablishedearlierinthecourseof
type 2 diabetes does reduce subsequent
cardiovascular events, even though the
differential in A1C among patients ini-
tiallytreatedintensivelydissipatedwithin
1 year.
By design, our study focused on pa-
tients with diabetes and suboptimal glu-
cose control. Many of these patients did
nothaveconcurrentissuesrelatedtotheir
blood pressure or lipid levels. Perhaps for
this reason and the short duration of the
trial, we did not observe large differences
intheseoutcomes,despitecontinuousac-
tive medication management and self-
management education for blood
pressure and lipids in ACMHT partici-
pants.Asigniﬁcantlyhigherproportionof
ACMHT (79.7%) versus CC partici-
pants (59.4%) achieved the LDL choles-
terol target of 100 mg/dl at 6 months. A
longer trial using HT in a different patient
population might provide a better assess-
ment of the value of this intervention in
improving management of blood pres-
sureandlipids,assuggestedbythe5-year
Informatics for Diabetes Education and
Telemedicine (IDEATel) trial (18).
Although the present study was con-
ducted in participants receiving care
within the VA system, our ﬁndings are
relevanttootherpatientpopulations.The
IDEATel study, an RCT of 1,665 under-
served diabetic Medicare recipients
whose age, educational status, and socio-
economic status was similar to partici-
pants in the present study, compared the
use of home telemonitoring combined
with nurse case management under the
supervision of an endocrinologist with
usual care in community settings (18).
Small but signiﬁcant reductions in A1C,
blood pressure, and LDL cholesterol fa-
voringtheinterventiongroupwerefound
at5years(18).AlthoughIDEATeldidnot
combine active medication management
by a nurse practitioner with HT, the latter
is now accepted practice in many health
care organizations outside the VA. Use of
only one provider in the present study
may limit the ability to generalize our
ﬁndings to similar interventions con-
ducted by multiple providers. However,
employment of a standardized treatment
protocol supports the relevance of our re-
sults to other clinical settings. Additional
research is needed to examine the ques-
tions of whether active care management
with home telemonitoring is a cost-
effective approach for management of pa-
tients who have not achieved adequate
glycemic control with usual care and
whether the short-term improvements in
glycemic control observed with active
care management with home telemoni-
toring can be sustained with less resource
utilization.
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